Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network.

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.

2.

Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.

Ehlers MR, Nepom GT.

Rev Diabet Stud. 2012 Winter;9(4):359-71. doi: 10.1900/RDS.2012.9.359. Epub 2012 Dec 28. Review.

3.

Clinical application of regulatory T cells in type 1 diabetes.

Marek-Trzonkowska N, Myśliwec M, Siebert J, Trzonkowski P.

Pediatr Diabetes. 2013 Aug;14(5):322-32. doi: 10.1111/pedi.12029. Epub 2013 Apr 30. Review.

PMID:
23627860
4.

Interleukin-2 and type 1 diabetes: new therapeutic perspectives.

Hartemann A, Bourron O.

Diabetes Metab. 2012 Nov;38(5):387-91. doi: 10.1016/j.diabet.2012.05.006. Epub 2012 Jul 5. Review.

PMID:
22771204
5.

IL-2 therapy in type 1 diabetes: "Trials" and tribulations.

Long SA, Buckner JH, Greenbaum CJ.

Clin Immunol. 2013 Dec;149(3):324-31. doi: 10.1016/j.clim.2013.02.005. Epub 2013 Feb 22. Review.

PMID:
23499139
6.

Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.

Dwyer CJ, Ward NC, Pugliese A, Malek TR.

Curr Diab Rep. 2016 Jun;16(6):46. doi: 10.1007/s11892-016-0739-1. Review.

PMID:
27076179
7.

Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.

Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D.

Curr Diab Rep. 2014 Dec;14(12):553. doi: 10.1007/s11892-014-0553-6. Review.

PMID:
25344788
8.

Role of regulatory T cells for the treatment of type 1 diabetes mellitus.

Jaeckel E, Mpofu N, Saal N, Manns MP.

Horm Metab Res. 2008 Feb;40(2):126-36. doi: 10.1055/s-2008-1042427. Review.

PMID:
18283631
9.

Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.

Li CR, Baaten BJ, Bradley LM.

J Mol Cell Biol. 2012 Feb;4(1):38-47. doi: 10.1093/jmcb/mjr040. Epub 2011 Nov 24. Review.

10.

Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Pham MN, von Herrath MG, Vela JL.

Front Immunol. 2016 Jan 11;6:651. doi: 10.3389/fimmu.2015.00651. eCollection 2015. Review.

Supplemental Content

Support Center